Poster Session I

Return to the Agenda:

NOTE: You can search this page by using your browser's "Find" function
(under the "Edit" menu in Netscape Navigator/Communicator and Microsoft Internet Explorer)

Allorecognition/Antigen Processing and Presentation

#135 Increased B7 expression by antigen presenting cells from African-Americans.

A Hutchings, WM Purcell and MR Benfield, Birmingham, AL and Bristol, UK

#136 TCR b-chain repertoire use in response to cardiac allografts disparate for one class I MHC molecule.

J Fang, X Que, A Mhoyan and H Shirwan, Glenolden, PA

#137 The sera from highly sensitized patients contains a non-HLA class I antibody that stimulates B cells to produce cytotoxic HLA class I antibodies.

CJ Cardella, N Hack, E Friedman, S Angra and T McKnight, Toronto, ON, Canada

#138 Induction of long-term graft survival in the absence of immunosuppression by replacement of acutely rejected renal allografts.

SG Tullius, A Reutzel-Selke, M Nieminen-Kelhä, S Jonas, WO Bechstein, P Neuhaus and HD Volk, Berlin, Germany

AST Poster of Distinction
#139 b7 integrins are important, but not indispensable to intestinal allograft rejection.

R Kellersmann, R Zhong, D Grant, A Blomer, B Garcia, N Wagner, K Rajewsky, H Wang, W Liu, A Jevnikar and A Lazarovits, London, ON, Canada and Cologne, Germany

AST Poster of Distinction
#140 Analysis of cytomegalovirus-specific cytotoxic T-lymphocytes (CMV-CTLs) in liver transplant patients (LTPt).

S Singhal, JC Shaw, J Ainsworth, M Hathaway, HJ Paris, K Ward, PAH Moss and DJ Mutimer, Birmingham, UK

#141 MLR responses to allogeneic MHC class II peptides requires priming of the responder.

GW Haller, SM Kunisaki, S Germana, C LeGuern and DH Sachs, Boston, MA

#142 Acute skin graft rejection induced by b2 microglubin associated minor transplantation antigens: characterization in microglubin-deficient mice.

M Surquin, A Le Moine, FX Demoor, V Flamand, M Pretolani, M Goldman and D Abramowicz, Brussels, Belgium and Paris, France

#143 In vitro antigen presenting cell function is deficient in stable lung transplant recipients.

C Knoop, J Ismaili, F Bulté, D Abramowicz, M Goldman and M Estenne, Brussels, Belgium

#144 Sensitization against donor mismatched HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome.

S Reznik, A Jaramillo, M Sayegh, G Patterson and T Mohanakumar, St. Louis, MO and Boston, MA

#145 Activation of a non-specific immune response in cadaveric donor livers.

J van der Hoeven, G Molema, P de Vos, A Girbes, G Ter Horst and R Ploeg, Groningen, The Netherlands

#146 Evidence for the critical requirements of costimulation signal strength and early CD154-dependent events in murine skin allograft survival.

D Dean, A Kirk, G Gray, A Celniker and D Harlan, Bethesda, MD and Cambridge, MA

#147 Distinct patterns of soluble HLA class I and free heavy chain release in lung transplant patients during rejection versus CMV infection.

LD DeVito-Haynes, E Jankowska-Gan, A Zeevi, K Spichty, J Dauber, A Iacono, R Keenan, B Griffith, K Meyer, RB Love and WJ Burlingham, Madison, WI and Pittsburgh, PA

#148 Indirect allorecognition in quiescent pediatric and adult thoracic allografts.

SA Webber, C Bentlejeweski, A Fitzimmons, GJ Boyle, SA Miller, YM Law, K McCurry, S Murali, BP Griffith and A Zeevi, Pittsburgh, PA

#149 Long-term small bowel allograft function is associated with split tolerance.

C Otto, W Timmermann, M Gasser, D Meyer, HJ Gassel, K Ulrichs and A Thiede, Wuerzburg, Germany

#150 Indirect recognition and allospecific T suppressor cells in liver allograft recipients.

E Renna-Molanjoni, N Suciu-Foca and R Cortesini, Rome, Italy and New York, NY

#151 Trans-vivo assessment of human alloreactive DTH responses, a tool for post-transplant monitoring.

AM VanBuskirk, RP Pelletier, L Carrodeguas and CG Orosz, Columbus, OH

#152 Hyperbaric oxygen culture-induced immune non-responsiveness is likely mediated by altered-antigen presentation.

D MacKenzie and D Hullett, Madison, WI

#153 CTLA4Ig fails to prevent intestinal allograft rejection due to an inability to inhibit CD8 T cell responses.

KA Newell, G He, Z Guo, O Kim, J Hart, M Collins, JR Thistlethwaite, Jr. and JA Bluestone, Chicago, IL and Boston, MA

#154 Organization, structure and sequence of the rat TCR b genomic loci.

AR Iyengar, AM Waaga, CC Magee, DR Beier, CN Adra, CB Carpenter and MH Sayegh, Boston, MA

#155 Interferong protects liver allografts from early immune injury.

TS Mele, NM Kneteman, L-F Zhu, V Ramassar and PF Halloran, Edmonton, AB, Canada

Back to Top

Cytokines/Chemokines

#156 Allotrap1258 mediated inhibition of TNFa production: analysis of the mechanism of action.

S Iyer, D Chevrier, C Cuturi, N Mori, R Buelow and JP Soulillou, Menlo Park, CA and Nantes, France

#157 Unique cytokine genotypes associated with chronic rejection and chronic rejection-free states in heart recipients.

NL Reinsmoen, AM Jackson, F Cross, I Hutchinson, K Savik, S Ormaza, L Miller and FE Ward, Durham, NC;Manchester, UK and Minneapolis, MN

#158 The chemokine rantes colocalizes with allograft infiltrating CD4⁺ T cells through chemokine receptors CCR1 and CCR5.

S Koga, A Kapoor, H Toma, AC Novick and RL Fairchild, Cleveland, OH and Tokyo, Japan

#159 NK cells do not utilize IFNg production or perforin mediated cytolysis to upregulate chemokine gene expression in allogeneic skin grafts.

K Morita, Y Watarai and R Fairchild, Cleveland, OH

#160 Differential analysis of regulatory cytokines in acquired thymic tolerance induced by MHC class I peptide with the dominant epitope.

NC Chowdhury, M Gorrovillo, M Ingram, MX Jin and SF Oluwole, New York, NY

#161 Mechanisms of tolerance induction in 2^nd renal allografts of a chronic rejection model.

SG Tullius, E Graser, M Nieminen-Kelhä, A Reutzel-Selke, S Jonas, WO Bechstein, P Neuhaus and HD Volk, Berlin, Germany

#162 Donor treatment with Flt3 ligand augments microchimerism in tacrolimus-immunosuppressed allogeneic bone marrow recipients.

MA Antonysamy, AE Morelli, PJ O’Connell, NB Zurowski, T Takayama and AW Thomson, Pittsburgh, PA

AST Poster of Distinction
#163 Autonomous growth of EBV transformed B cell lymphomas in patients with PTLD may involve constitutively acti-vated cytokine signaling pathways.

RR Nepomuceno, PR Beatty, SM Krams and OM Martinez, Stanford, CA

AST Poster of Distinction
#164 Fractalkine expression is upregulated in renal allograft rejection.

LA Robinson, DN Howell, AM Fong, DD Patel and TM Coffman, Durham, NC

#165 IFN-g polymorphism and its impact on delayed graft function of kidney allografts.

A Asderakis, D Sankaran, P Sinnott, P Dyer, I Hutchinson and R Johnson, Manchester, UK and London, UK

#166 Cytokine response profiles selectively induced by recombinant hepatitis C virus (HCV) antigens or chemically synthesized peptides.

DD Eckels, N Tabatabai, H Wang, TH Bian and JC Gill, Milwaukee, WI

#167 Expression of chemokines and chemokine receptors in human cardiac allografts: association with CD3+ T cell infiltrates and rejection.

M Melter, J Fang, G McMahon, W Hancock, P Ganz and DM Briscoe, Boston, MA

#168 Th2 intracellular cytokine patterns in kidney recipients hyporesponsive to donor antigen.

NL Reinsmoen, A deOliveira, S Peplinski and AJ Matas, Durham, NC and Minneapolis, MN

#169 Acutely rejected murine cardiac allografts in interferon-gamma-deficient recipients show increased macrophage infiltration, elevated MIP-2, and markedly decreased RANTES expression.

J Stinn, K Shimizu, Y Furakawa, G Becker, P Libby and R Mitchell, Boston, MA

#170 Cytotoxic lymphocyte effector gene expression in bronchoalveolar lavage of lung transplant patients during CMV infections versus acute rejection.

PM Soccal, A Jani, S Chang, M Pavlakis and RL Doyle, Stanford, CA

#171 Expression of granulysin in peripheral blood mononuclear cells (PBMC) correlates with acute renal allograft rejection in children.

M Sarwal, A Jani, S Chang, A Krensky and M Pavlakis, Palo Alto, CA

#172 Chemokine expression in nerve allografts.

R Midha, CA Munro, V Ramakrishna, T Matsuyama and RM Gorczynski, Toronto, ON, Canada

#173 ELR-CXC chemokines cause transplantation injury through CXCR2-mediated neutrophil recruitment.

ME DeVries, L Ran, R Rahimpour, G Pickering, J Wang, G Wang, R Feldman, S Chakrabarti, R Zhong and DJ Kelvin, London, ON, Canada

#174 Intragraft expression of granulysin and perforin in acute human renal allograft rejection.

M Sarwal, A Jani, S Chang, P Huie, C Tao, R Sibley and M Pavlakis, Palo Alto, CA

#175 Rapamycin induces TGFb production in lympocytes.

IL Dodge, XC Li and TB Strom, Boston, MA

#176 Chemokines MIP-2 and MCP-1/JE mediate leukocyte recruitment after reperfusion.

J Yun, M Fischbein, H Laks, M Fishbein, M Espejo, F Hemat and A Ardehali, Los Angeles, CA

#177 Bile duct ligation (BDL) results in increased liver IL-10 production and protection against renal ischemia in mice.

DR Jeyarajah, M Kielar, S Devraj and CY Lu, Dallas, TX

Back to Top

Chronic Rejection

#178 Chronic cyclosporine reduction deveases apoptosis and p53 expression in human renal biopsies with improvement of renal pathological score and renal function.

C Wei, H Song, K Seta, M Kinjo, P Lau, JC Fink, C Drachenberg, J Papadimitriou, ST Bartlett and MR Weir, Baltimore, MD

#179 Combined SDZ RAD and cyclosporine a prevent fibrosis, but not lymphocyte infiltration, in experimental obliterative airways disease.

H Levrey, PB Bitterman and J Jessurun, Minneapolis, MN

#180 Cyclosporine but not rapamycin stimulates endothelin-1 secretion by endothelial cells: potential significance in transplant vasculopathy.

KC Floyd, DE Hricik and MS Simonson, Cleveland, OH

#181 Cyclosporine activates the endothelin converting enzyme: implications for acute and chronic nephrotoxicity.

WH Herman, D Hricik and MS Simonson, Cleveland, OH

#182 Allotrap 1258 inhibits chronic rejection by direct effects on smooth muscle cells.

W Li, L Lu, S Iyer, J Woo, MC Cornejo, JJ Fung, R Buelow and S Qian, Pittsburgh, PA and Menlo Park, CA

#183 Endothelin-1 mediates transplant vasculopathy and chronic rejection in LEW/F344 cardiac allografts.

M Simonson, A Robinson, W Herman, K Floyd, J Schulak and D Hricik, Cleveland, OH

#184 CMV strain-specific alterations induced in vascular endothelial cells: implications for chronic rejection.

R Srivastava, M Curtis, S Hendricks, W Burns and JD Hosenpud, Milwaukee, WI

#185 The relationship between donor age and prolonged ischemia and its effect on long-term graft outcome.

SG Tullius, A Reutzel-Selke, M Nieminen-Kelhä, F Egermann, S Jonas, WO Bechstein, HD Volk and P Neuhaus, Berlin, Germany

#186 Acceleration of chronic graft rejection by secondary donor-specific skin transplants.

SG Tullius, C Heidenhain, A Reutzel-Selke, M Nieminen-Kelhä, S Jonas, WO Bechstein, HD Volk and P Neuhaus, Berlin, Germany

#187 Myocardial work-load significantly affects graft atherosclerosis in heterotopically transplanted rat heart allografts.

B Asfour, H Baba, C-L Chen, W Baldwin, RH Hruban, T Kohl, C Schmid, H Rotering, HH Scheld and BJ Byrne, Muenster, Germany and Baltimore, MD

#188 Pravastatin prevents transplant vasculopathy by inhibiting p21^ras activation pathway and upregulating the expression of ‘protective’ hemoxygenase-1 gene.

H Kato, B Ke, DK Imagawa, R Buelow, RW Busuttil and JW Kupiec-Weglinski, Los Angeles and Menlo Park, CA

#189 Influence of nephron mass in the development of nephrosclerosis after renal warm ischemia.

JM Cruzado, J Torras, I Herrero, M Hueso, M Riera, E Condom, L Espinosa, J Bover, N Lloberas and JM Grinyó, Barcelona, Spain

#190 The effects of enalapril and L-158809 on myocardial beta-adrenergic receptor density in transplanted rat hearts.

T Nakame, A Iguchi, H Yokoyama, M Ohmi and K Tabayashi, Sendai, Japan

#191 Intragraft expression of TGF b 1 by a novel quantitative RT-PCR-elisa in long lasting kidney receptors.

V Mas, J Sena, A Diller, S Albano, C Giraudo, T Alvarellos, P Massari and G De Boccardo, Cordoba, Argentina

#192 Development of anti-airway epithelial cell specific antibodies in lung transplant recipients with bronchiolitis obliterans syndrome.

A Jaramillo, B Naziruddin, MA Smith, D Phelan, EP Trulock, JP Lynch, JD Cooper, A Patterson and T Mohanakumar, St. Louis, MO

AST Poster of Distinction
#193 CD4⁺ T lymphocytes are necessary for development of cardiac allograft vasculopathy.

MP Fischbein, J Yun, H Laks, MC Fishbein, K Ebrahimi, B Bonavida and A Ardehali, Los Angeles, CA

#194 A new marker in allograft coronary vasculopathy immunolocalizes to the proliferating neointima.

SE Crawford, C Mavroudis, CL Backer, Y Mu, L Huang, AJ Rocchini, E Pahl and V Stellmach, Chicago, IL

#195 The effect of blockade of CD28/B7 costimulatory pathway and donor bone marrow transplantation on the development of chronic rejection.

J Tang, V Subbotin, H Sun, L Valdivia, JJ Fung and AS Rao, Pittsburgh, PA

AST Poster of Distinction
#196 Panoramic reduction of chronic histopathology in B cell KO recipients of cardiac allografts.

RP Pelletier, AM VanBuskirk and CG Orosz, Columbus, OH

#197 A new synthetic VLA-4 blocker prevents development of chronic rejection in a rat cardiac transplant model.

M Richter, V Wehner, I Waligura, D Schramm, A Tannapfel, M Kock, B Maybaum, V Falk, H Richter and Fw Mohr, Leipzig, Germany and Frankfurt, Germany

#198 In 6 month protocol renal transplant biopsies, longterm allograft outcome is predicted by using the Banff chronic score or quantitation of fibrosis using image analysis of sirius red staining.

PC Grimm, J Jeffery, P Nickerson, R McKenna, S Benzik, G Elzbieta, PE Birk, J Gough and DN Rush, Winnipeg, MB;Winnnipeg, MB;Calgary, AB and Winnipeg, MB, Canada

#199 Chronic rejection: role of CD8+ T lymphocytes on medial smooth muscle cell.

JF Legare, T Issekutz, TDG Lee and G Hirsch, Halifax, NS, Canada

#200 Do vascular compartments differ in the development of chronic rejection? AT1 blocker candesartan versus ace blocker enalapril in an experimental heart transplant model.

M Richter, B Maybaum, H Richter, HG Olbrich and FW Mohr, Leipzig, Germany and Frankfurt, Germany

Back to Top

Experimental Immunosuppression

#201 Pharmacodynamics (PD) of mycophenolate mofetil (MMF) after heart transplantation identify new mechanism of action and correlate with severity of rejection.

MJ Barten, T van Gelder, JF Gummert, K Boecke, ME Billingham and RE Morris, Stanford, CA

#202 Potencies of immunosuppressive drugs for inhibition of signal 1- and signal 2-induced expression of lymphocyte cell surface activation antigens using whole blood assays.

MJ Barten, JF Gummert, T van Gelder, R Shorthouse and RE Morris, Stanford, CA

#203 A humanized anti-CD3 antibody HuM291 mediates complete and reversible T-cell depletion in chimpanzees.

D-H Hsu, JD Shi, M Homola, TJ Rowell, J Moran, D Levitt, B Druilhet, J Chinn, Ch Bullock and C Klingbeil, Fremont, CA and New Iberia, LA

#204 The novel IMPDH inhibitor VX-497 prolongs skin graft survival and improves GvHD in mouse.

CJ Decker, AD Heiser, T Faust, G Ku, S Mosely and E Nimmesgern, Cambridge, MA

#205 FTY 720 efficiently prolongs allograft survival by suppressing T cell-dependent and T cell-independent immunity.

V Brinkmann, H-J Schuurman, D Pinschewer, K Chiba and R Hof, Basel and Zuerich, Switzerland and Saitama, Japan

#206 Sirolimus exacerbates CsA-induced nephrotoxicity by raising CsA blood through levels, but does not impair renal function by a pharmacodynamic interaction.

H Podder, SM Stepkowski, KL Napoli and BD Kahan, Houston, TX

#207 TGF-b provides the rationale for the synergistic immunpsuppression with rapamycin (RAPA), cyclosporine (CsA) and tacrolimus (TAC).

A Khanna, Milwaukee, WI

#208 Placental protein 14 inhibits IL-1b and TNFa mRNA expression in PHA-stimulated human PBMC.

DM Cibrik, J Rachmilewitz, MC Weber and ML Tykocinski, Cleveland, OH

#209 A short course of high dose thymoglobulin induces lymphocyte depletion in the non-human primate.

C Sturgeon, K Ferrer, J Regan, J Schnell, R Buelow and A Bartholomew, Chicago, IL and Menlo Park, CA

#210 Pooled human gammaglobulin (IVIG) inhibits the mixed lymphocyte reaction (MLR) through modulation of surface molecules on antigen presenting cells (APC).

M Toyoda, A Pao, A Petrosian and SC Jordan, Los Angeles, CA

#211 The effect of cyclosporine A based combination therapy on bone, muscle & tendon rejection in a composite tissue allograft (CTA) model.

T Tecimer, J Edelstein, M Shirbacheh, J Ustuner, M Zdichavsky, Tü Tecimer, C Maldonado, WC Breidenbach, MB Ray, JW Jones and JH Barker, Louisville, KY

#212 The effect of tacrolimus based combination therapy on muscle and bone rejection in a pre- clinical composite tisse allograft model.

J Edelstein, T Tecimer, T Ustuner, M Zdichavsky, M Shirbacheh, Tü Tecimer, C Maldonado, WC Breidenbach, MB Ray, JW Jones and JH Barker, Louisville, KY

#213 Effect of sirolimus on plasma lipid and lipoprotein levels and metabolism in renal transplant patients.

JD Morrisett, CM Ballantyne, HJ Pownall, AR Opekun, JS Jaffe, S Oppermann and BD Kahan, Houston, TX and Philadelphia, PA

#214 The antiproliferative effect of malononitrilamides (MNAs) in vitro and in vivo seems to be mediated by inhibition of de novo pyrimidine biosynthesis.

HU Schorlemmer, R Kurrle, R Schleyerbach and B Kirschbaum, FrankfurtMain, Germany

AST Poster of Distinction
#215 Cyclosporine differentially inhibits the expression of key functional molecules in in vitro generated dendritic cells: association with reduced nuclear translocation of NF-KB.

J Lee, RW Ganster, GJ Burckart, D Geller, AW Thomson and L Lu, Pittsburgh, PA

#216 Malononitrilamides (MNAs) exert their immunosuppressive activity primarily by inhibition of dihydroorotate dehydrogenase (DHODH).

HU Schorlemmer, U Milbert, R Schleyerbach and B Kirschbaum, FrankfurtMain, Germany

#217 Interaction of the immunosuppressant LF 08-0299 (Tresperimus) and analogues with the constitutive heat shock protein 70.

S Komesli, C Dumas and P Dutartre, Daix, France

#218 Azodicarbonamide as a new immunosuppressive agent.

Ismaili Jamila, J Tassignon, A Lemoine, O Leo, M Vandevelde and M Goldman, Brussels, Belgium

#219 Graft rejection in mycophenolic acid (MPA) treated heart transplant recipients is predicted by changes in lymphocyte function over time (pharmacodynamics).

JF Gummert, MJ Barten, Y Wang, ME Billingham and RE Morris, Stanford, CA

#220 Synergistic effect of low molecular weight hyaluronic acid (LMWHA) and cyclosporine A (CsA) in prolingation of rat kidney allograft survival.

R Buelow, S Qi, D Liu, D Xu, J Peng, D Daloze, W Zhang and H Chen, Montreal, PQ, Canada and USA

AST Poster of Distinction
#221 The IMPDH inhibitor VX-497 is the first rationally synthesized immunosuppressant to prolong allograft survival.

JF Gummert, MJ Barten, K Boeke, EJ Leon, CJ Decker, E Nimmesgern, ME Billingham and RE Morris, Stanford, CA and Cambridge, MA

#222 Comparison of FK506- and D-allose-based immunosuppression after allogenic orthotopic liver transplantation in rats.

HM Akram, I Hamamoto, H Wakabayashi, F Goda, S Kobayashi, T Maeba and H Maeta, Kagawa, Japan

#223 Pharmacodynamics of FTY 720 in rats.

K Chiba, S Nakayama, N Arima and R Kawai, Tokyo, Japan and Basel, Switzerland

#224 Differences among organs in calcineurin inhibition by cyclosporine may explain toxicity patterns in vivo.

S Palomo, J Noujaim, L Helms and PF Halloran, Edmonton, AB, Canada and Mexico City, Mexico

#225 Modulators of P-glycoprotein-mediated transmembrane transport inhibit T-cell proliferation in vitro.

MH Frank, MD Denton, SJ Khoury, DM Briscoe and MH Sayegh, Boston, MA

#226 Rhesus renal allografts contain non-destructive activated lymphocytic infiltrates following anti-CD154 therapy.

RE Baumgartner, NB Patterson, J Berning, L Burkly, R Germond, DM Harlan, R Kampen, DK Tadaki, SG Sabnis and AD Kirk, Bethesda, MD; Cambridge, MA and Washington, DC

AST Poster of Distinction
#227 Coexpression of Fas ligand and Bcl-2 in rat liver transplantation.

A Tamura, X-K Li, N Funeshima, T Okuyama, S Enosawa, H Amemiya, Y Kaneda and S Suzuki, Tokyo and Osaka, Japan; and

#228 Analysis of gene transfer efficacy in rat islets with adenovirus, adeno-associated virus and baculovirus.

B Le Mauff, F Boeffard, L Tesson, G Chadeuf, S Douthe, A Salvetti, P Moullier, JP Soulillou and I Anegon, Nantes, France

#229 Inhibition of renal allograft rejection by blocking the costimulatory pathway in primates.

M Ossevoort, J Ringers, E Kuhn, K Lorré, L Boon, Y van den Hout, JA Bruijn, M de Boer, P de Waele and M Jonker, Rijswijk, and Leiden, The Netherlands; Gent, Belgium and Amsterdam, The Netherlands

#230 Pharmacokinetics of antithymocyte globulins: effects of low dose versus high dose of thymoglobuline^® in a non human primate model.

X Préville, N Bonnefoy-Berard, R Buelow, J Tiollier, A Oubenaissa and JP Revillard, Lyon, France and Menlo Park, CA

#231 Cooperativity of a 1,25-dihydroxyvitamin D₃ non-steroidal E-ring analog with classical immunosuppressants.

E van Etten, D Branisteanu, A Verstuyf, R Bouillon, M Waer and C Mathieu, Leuven, Belgium and Iasi, Romania

#232 Administration of Fas/Fc fusion protein suppresses delayed-type hypersensitivity responses in mice.

ML Lipman and Y Shen, Montreal, PQ, Canada

#233 Stable prodrugs of n-Butyric acid: suppression of T cell alloresponses in vitro and prolongation of heart allograft survival in a fully allogeneic rat strain combination.

GA Böhmig, P-M Krieger, MD Säemann, H Karimi, F Mühlbacher and GJ Zlabinger, Vienna, Austria

#234 Prolonged survival of islet grafts in NOD mice by blockade of the CD40-CD40L costimulatory pathway.

L Inverardi, RD Molano, T Berney, H Li, NS Kenyon, LC Burkly and C Ricordi, Miami;Cambridge, MA and Miami, FL

#235 Cyclosporine A stimulation of vascular smooth muscle cell proliferation is associated with increased expression of 14-3-3_gprotein.

JW Jones, S Guo, S Su, R Fernandez and SJ Hu, Louisville, KY

Back to Top

Tolerance

#236 Immunological tolerance mediated by donor bone marrow is dependent on the presence of a functional Fas gene in the recipients.

DR Goldstein, T Chang, SD Sweeney, JK Kirklin, JM Thomas and JF George, Birmingham, AL

#237 Induction of allospecific immunotolerance to rat tracheal allografts with intra-portal injection of UVB treated donor antigen.

EM Genden, SE Mackinnon and MW Flye, New York, NY and St. Louis, MO

#238 Characterization of donor specific hyporeactivity after donor bone marrow administration.

A Hirano, L Tristano, T Takayama and ML Jordan, Pittsburgh, PA

#239 Intrathymic immune nonresponsiveness with class I MHC allopeptides is associated with suppressive immune mechanisms.

A Mhoyan, X Que and H Shirwan, Glenolden, PA

#240 Stem cells purified from bone marrow of FLT3-ligand-treated mice exhibit reduced engraftment-potential.

YM Mueller, BG Exner and ST Ildstad, Glenolden, PA

#241 Class I MHC protein tolerogens for rat cardiac allografts across major histocompatibility barriers.

J Perez, J Yu, P Song, S Stepkowski and BD Kahan, Houston, TX

#242 Host CD8⁺ and ab-TCR⁺ cells play a role in regulating engraftment of syngeneic bone marrow.

BG Exner, Y Mueller, M Neipp and ST Ildstad, Glenolden, PA

#243 Cytokine gene transfer in heart allografts does not induce tolerance in high responder strain combination.

M Lehmann, K Risch, F Cifire, J Brock, P Reinke, HD Volk and T Ritter, Berlin, Germany

#244 IL-4 is required for tolerance induction induced by depleting anti-CD4 mAB.

XX Zheng, K Kawamoto, XC Li, Y Li, Y Tian and TB Strom, Boston, MA

#245 Systemic, not local, administration of liver-derived DC induce donor-specific hyporesponsiveness associated with increased CD4⁺ and GR-1⁺ cells in allografts.

Y-J Chiang, L Lu, JJ Fung and S Qian, Pittsburgh, PA

#246 Influence of the thymus on sensitization and the requirement of antigen for the maintenance of tolerance to renal allografts in miniature swine.

K Yamada, J Fishbein, PR Gianello, FL Ierino, A Shimizu, RB Colvin and DH Sachs, Boston, MA

#247 Induction of T cell tolerance in miniature swine with allogeneic thymus transplants across a class I barrier.

GW Haller, N Esnaola, K Yamada, A Wu, A Shimizu, RB Colvin, M Sykes and DH Sachs, Boston, MA

#248 Donor hepatocytes, but not intrahepatic leukocytes, induce graft-specific tolerance.

H Schiller, KAY Ott, K Richter, F Fandrich, M Krönke and N Zavazava, Kiel, Germany

#249 Soluble, recombinant MHC class I molecules induce indefinite graft survival.

D Behrens, K Lange, M Krönke and N Zavazava, Kiel, Germany

#250 Stability of the tolerance phenotype after withdrawal of immunosuppressive drug ther- apy: influence of local and genetic factors influencing TNFa and TGFb expression.

WJ Burlingham, PJ O’Connell, JD Pirsch, BN Becker, AD Kirk, LM Jacobson, LT Chin, S Kusaka, HW Sollinger, V Pravica and I Hutchinson, Madison, WI and Manchester, UK

#251 Distinct tolerance pathways in liver transplant recipients.

H Kato, AJ Coito, D Zhao, RW Busuttil and JW Kupiec-Weglinski, Los Angeles, CA

#252 Stats in murine allo-tolerance and allo-rejection responses ex vivo.

SD Moffatt and SM Metcalfe, Cambridge, UK

#253 Cardiac allograft long-term functional tolerance without immunosuppressive drugs in mice transgenic for a suicide gene.

N Raynal-Raschilas, E Braunberger, A Carpentier, D Klatzmann and D Glotz, Paris, France

#254 Prolonged survival of baboon renal allografts using idarubicin conjugated anti-CD4 monoclonal antibodies.

JF Botha, W Linley, G Davison, A Mall, V Tandon, I McKenzie, D Kahn and M Sandrin, Cape Town, South Africa

AST Poster of Distinction
#255 Identification of immunodominant peptides following DST and rejection in the LEW.1W to LEW.1A model.

BJW van Denderen, H Peche, M-C Cuturi and J-P Soulillou, Nantes, France

#256 Tolerance induction in a rat osteomyocutaneous allograft model across major immunologic barrier.

LS Yeh, SM Hou, YJ Chen, YS Liou and TC Liao, Taipei, Taiwan

#257 Evidence for negative selection of alloreactive T cells in the thymus of allograft recipients.

Sherry Rohekar, Jiao-Xin Wang, Subrata Chakrabarti, Robert Zhong and Joaquín Madrenas, London, ON, Canada

#258 Acute rejection and cardiac allograft vasculopathy (CAV) following thymoheart transplantation in miniswine.

M Menard, K Mawulawde, K Yamada, M Schwarze, RS Lee, K Allison, E Pillsbury, S Houser, D Sachs and J Madsen, Boston, MA

AST Poster of Distinction
#259 Augmentation of donor cell chimerism by simultaneous use of Flt3L and co-stimulatory blockade.

A Salam, V Subbotin and AS Rao, Pittsburgh, PA

#260 Influence of inflammation on portal venous tolerance.

LE Wrenshall and G Gersuk, Seattle, WA

#261 Important role of NKR-P1⁺TCR^ab(NKT) cells to prevent IDDM recurrence in rat pancreas transplantation.

M Tori, T Ito, T Yumiba, M Miyasaka, H Kiyono, H Matsuda, M Nozawa and R Shirakura, Suita, Japan

#262 IL-2 regulates FLIP expression in human CD4⁺ lymphocytes.

S Alexander, Y Refaeli, A Abbas and A Lichtman, Boston, MA

AST Poster of Distinction
#263 Analysis of IL-2 transcriptional events in anergized human T-cells.

O Heisel and P Keown, Vancouver, BC, Canada

#264 An OX-2:FC immunoadhesin is a potent immunosuppressant facilitating allo- and xeno-renal graft survival.

RM Gorczynski, Z Chen, J Hu, J Lei, G Yu and J Ni, Toronto, ON, Canada

#265 Rare circulating donor cells inhibit anti-donor cytolytic activity during peripheral tolerance.

L Chin, S Kusaka, H Sollinger and W Burlingham, Madison, WI

#266 Peripheral tolerance to non-inherited maternal HLA antigens: loss of ‘direct pathway’ T cell receptor mRNA signals during breakdown of tolerance in a renal transplant recipient.

S Kusaka, AP Grailer, JH Fechner, E Jankowska-Gan, T Oberley, HW Sollinger and WJ Burlingham, Madison, WI

#267 Role of TGFb in cardiac allograft acceptance.

AA Bickerstaff, D Xia and CG Orosz, Columbus, OH

#268 Rejection of allogeneic hepatocytes in hosts with long-term surviving MHC matched heart allografts.

J Li, D Gao, E Wakely, CG Orosz and GL Bumgardner, Columbus, OH

#269 Immunological characteristics of intragraft NKR-P1⁺TCR_ab⁺ T (NKT) cells in rat hepatic allograft of natural acceptor and rejector.

A Ohkawa, T Ito, T Yomiba, A Maeda, M Tori, Y Sawai, T Kiyomoto, Y Akamaru and H Matsuda, Osaka, Japan

#270 Tolerance induction by perioperative intrathymic injection in a rat ‘high responder’ combination.

T Sawai, T Ito, T Yumiba, A Ohkawa, A Maeda, M Tori and T Kiyomoto, Suita, Japan

AST Poster of Distinction
#271 Mechanisms of cardiac allograft survival with blockade of CD40-CD40 ligand interactions.

K Shimizu, F Mach, U Schönbeck, P Libby and R Mitchell, Boston, MA

AST Poster of Distinction
#272 Mechanistic characterization of tolerance induced with ALS, donor bone marrow and sirolimus.

DA Hale, A Umemura, R Gottschalk, T Maki and AP Monaco, Boston, MA

#273 Different mechanisms of prolonged allograft survival induced by anti-donor class II antibodies or donor specific transfusion.

S Brouard, K Gagne, M Guillet, MC Cuturi, R Josien and JP Soulillou, Nantes, France

Back to Top

Tissue Injury

#274 Cell death in human lung transplantation: time course of apoptosis induction before, during and after transplantation.

S Fischer, SD Cassivi, AM Xavier, JA Cardella, RA Gladdy, M Lui and S Keshavjee, Toronto, ON, Canada

#275 Can S100 protein prevent neurological damage in heart transplant recipients?: experience on cardiopulmonary bypass.

D Gazzolo, P Masetti, S Marianeschi, R Abella, F Michetti, GP Ussia, A Cipriani, S Paesani, FS Iorio and CF Marcelletti, Modena, Italy

#276 Compound from tripterygium wilfordii protects isolated glomeruli from increased albumin permeability caused by FSGS serum.

M Sharma, R Sharma, XL Ge, RS Reddy, ET McCarthy and VJ Savin, Milwaukee, WI

#277 Oxidant stress in urine from cadaveric and living kidney donors as markers of renal injury.

DA Shoskes, R Webster, B Gunderson and A Shahed, Torrance, CA

#278 Complement mediates vascular inflammation and activation in allografts.

H Ota, W Hu, Z Qian, F Sanfilippo, RH Hruban and WM Baldwin, Baltimore, MD

AST Poster of Distinction
#279 Passive transfer of antibodies restores acute cardiac rejection in Ig knock out mice.

BA Wasowska, Z Qian, D Cangello, T Elshimi, T van Tran, W Hu, F Sanfilippo and WM Baldwin III, Baltimore, MD

#280 The effect of polyphenolic compounds on renal injury and repair.

EA Jones and DA Shoskes, Los Angeles, CA

AST Poster of Distinction
#281 Prevention and treatment of rejection-induced edema.

C Johnsson, R Hällgren, A Elvin, B Gerdin and G Tufveson, Uppsala, Sweden

#282 Adenovirus vector containing Fas-ligand gene induced lethal hepatitis in Fas-negative liver transplanted mice.

M Fujino, X-K Li, N Funeshima, T Okuyama, M Morita, A Sugioka, H Amemiya and S Suzuki, Tokyo and Aichi, Japan

#283 The bronchial circulation is important for the oxygen tension in peribronchial lung tissue.

M Kamler, M Bock, K Nowak, C Schlegel, U Herold, J Motsch, MM Gebhard, S Hagl and H Jakob, Heidelberg, Germany

#284 Development of apoptosis in the kidney during cold ischemia: evidence for a sensitizing role of cardiac arrest.

S Bellemare, N Vigneault, A Boucher, R Dandavino, V Pichette and M-J Hébert, Montreal, PQ, Canada

#285 Metabolic derangements following experimental renal ischemia/reperfusion injury: a direct comparison of cold and warm ischemia.

P Birk, M Ogborn, K Hills, E Nitschmann, M Cheang, P Grimm, P Nickerson, D Rush and P Williot, Winnipeg, MB, Canada

#286 Evaluation of ex vivo renal function following prolonged cold ischemia.

L Brasile, BM Stubenitsky, E Green and MH Booster, Schenectady, NY and Maastricht, The Netherlands

#287 Contact by activated lymphocytes promotes endothelial cell release of matrix: a model for endothelialitis?

AG Murray, AW McMahon, RC Nelson, C Phan and JF Elliott, Edmonton, AB, Canada

#288 Selective blockade of the endothelin A receptor improves experimental postransplant renal failure.

M Schaub, C Braun, S Vetter, T Conzelmann, M Kirchengast, FJ van der Woude and P Rohmeiss, Mannheim, Germany and Ludwigshafen, Germany

#289 Elevation of cyclic AMP and cyclic GMP levels by phosphodiesterase3 (PDE3) inhibitor attenuates ischemia and reperfusion injury of canine livers.

H Ishikawa, M Taniguchi, T Suzuki, T Shimamura, MB Jin, H Horiuchi, J Iida, S Magata, K Ogata, R Yokota, M Fukai, A Kishida, H Furukawa and S Todo, Sapporo, Japan

#290 Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions.

M Kusus, DD Stapleton, JJL Lertora, EE Simon and AW Dreisbach, New Orleans, LA

#291 Cyclosporin A is not toxic to human islets.

IC Gerling, C Saba, DW Fraga and AO Gaber, Memphis, TN

#292 Inhibition of ischemia/reperfusion injury with the Na⁺/H⁺ exchange inhibitor cariporide (Hoe642) modulates immunogenicity of cardiac allografts and improves graft survival.

THW Stadlbauer, M Schaub, A Usselmann, P Wohlfahrt, P Rohmeiss, M Keil, U Albus, W Scholz, H Ruetten and AM Zeiher, Frankfurt, Germany and Mannheim, Germany

#293 Acute ciclosporine nephrotoxicity after heart transplantation in Lewis rats.

P Hildbrand, PLJ Wijngaard, J Laissue, S Shaw, X Huang and PJ Mohacsi, Bern, Switzerland and San Francisco, CA

#294 Hepatocyte growth factor becomes elevated after donor nephrectomy and renal transplantation.

PE Morrissey, R Gohh, J Centracchio, PN Madras, AP Monaco and LD Dworkin, Providence, RI

#295 A paradoxical effect of elevated potassium levels and temperature on heart function following storage.

WN Wicomb, San Francisco, CA

#296 Telomerase activity in liver allografts in rats.

YC Lin, S Goto, CM Lee, TL Pan, R Lord, KC Chiang, YJ Chen, CL Chen, T Tatsuma and S Kitano, Kaohsiung, Taiwan and Oita, Japan

#297 Compliment deposition in early cardiac transplant biopsies is associated with ischemic injury.

WM Baldwin, III, M Samaniego, EK Kasper, M Czader, AA Zachary, CA Rhode, F Sanfilippo and RH Hruban, Baltimore, MD

#298 Effect of endogenous adenosine augmentation by dipyridamole on ischemia and reperfusion injury of the liver.

M Taniguchi, S Magata, T Suzuki, T Shimamura, MB Jin, J Iida, H Horiuchi, K Ogata, H Ishikawa, M Fukai, R Yokota, A Kishida, H Furukawa and S Todo, Sapporo, Japan

#299 Increased intragraft trail/APO-2L gene expression in renal and liver transplantation.

J Strehlau, B Nashan, C v Schnakenburg, G Demirci, A Strasburg, G Offner and JHH Ehrich, Hannover, Germany

#300 Protective effect of protease inhibitor, Nafamostat mesilate(FUT-175), on ischemia reperfusion injury in canine liver.

H Horiuchi, T Suzuki, M Taniguchi, MB Jin, T Shimamura, M Fukai, R Yokota, J Iida, S Magata, K Ogata, H Ishikawa, A Kishida, H Furukawa and S Todo, Sapporo, Japan

#301 Ischemia time prolongation does not promote chemokine expression or leukocyte recruitment after heart transplantation.

J Yun, M Fischbein, H Laks, M Fishbein, M Shiroishi and A Ardehali, Los Angeles, CA

Back to Top

Kidney: Acute and Chronic Rejection

#302 Chronic allograft nephropathy: effect of cyclosporine reduction and addition of mycophenolate on progression of renal disease.

MR Weir, JC Fink, DS Hanes, M Traver, C Young, K Schofield, S Blahut, DK Klassen, CB Cangro, E Schweitzer and ST Bartlett, Baltimore, MD

#303 Higher cyclosporine levels decrease kidney rejection episodes without increasing nephrotoxicity.

SW Beman, CR Reckard, P Campbell, DE Johnson and TE Wasser, Allentown, PA

#304 Serum beta 2-microglobulin monitoring in cyclosporine treated renal transplant recipients.

DP Lange, ZC Schmittling and TP O’Connor, Springfield, IL

#305 Long-term renal allograft survival: Prognostic implication of donor source; severity, timing, and number of acute rejection episodes; and proteinuria.

K Manzoor, V Ram Peddi and MR First, Cincinnati, OH

#306 Acute rejection reduces creatinine clearance (Ccr) at 6 months following renal transplantation but does not affect subsequent slope of Ccr.

LG Hunsicker and LE Bennett, Iowa City, IA;Richmond, VA and

#307 Efficacy of a modified daclizumab regimen in preventing acute rejection in kidney and kidney-pancreas transplant recipients.

MS Golconda, SC Rayhill, MR First, YM Wu, JA Bertolatus, CP Thomas and LG Hunsicker, Iowa City, IA and Cincinnati, OH

#308 Chronic renal graft failure begins early, progresses at a constant rate which varies from graft to graft, and occasionally arrests.

MA Baltzan, Sr. and AS Shoker, Saskatoon, SK, Canada

#309 Decreased acute kidney transplant rejection is associated with decreased chronic rejection.

AJ Matas, K Gillingham, A Humar, DL Dunn, W Payne, DER Sutherland and JS Najarian, Minneapolis, MN

AST Poster of Distinction
#310 Intra-renal expression of fibrogenic genes in renal allografts with tacrolimus and cyclosporine nephrotoxicity.

A Khanna, B Bresnahan, M Plummer, C Johnson, A Roza, M Adams and S Hariharan, Milwaukee, WI

#311 A two dose regimen of daclizumab (Zenapaz) in high-risk renal transplant recipients.

M Millan, M Pavlakis, E Alfrey, O Salvatierra, D Dofoe and J Scandling, Stanford, CA

#312 Determinants of recurrent acute rejection in kidney transplant recipients.

A Humar, A Moss, B Suhr, K Gillingham and A Matas, Minneapolis, MN

#313 Improved renal allograft survival but increased incidence of diabetes in tacrolimus-treated inner-city renal transplant patients at two year follow-up.

MS Markell, N Pervez, U Suresh, D Shamrakov, A DiBenedetto, N Sumrani, DA Distant, JH Hong and BG Sommer, Brooklyn, NY

#314 Factors influencing outcome in flow cytometry crossmatching for primary renal transplants.

H Abou El Fettouh, DJ Cook, E Bishay, S Flechner, D Goldfarb, C Modlin, V Dennis and AC Novick, Cleveland, OH

#315 Race is more important than early rejection in predicting chronic rejection: a multivariate analysis of the UNOS data.

R Isaacs, S Nock, C Spencer, R Sawyer, R Bollu and P Lobo, Charlottesville, VA

#316 Massive elevation of systemic procalcitonin levels in kidney transplant patients treated with anti-CD3 monoclonal antibody (OKT3).

R Sabat, W-D Döcke, C Höflich, M Oppert, B Windrich, H-D Volk and P Reinke, Berlin, Germany

AST Poster of Distinction
#317 Identification of early immune and non-immune events as risk factors for late clinical rejection.

D Rush, J Jeffery, J Gough, P Grimm, P Birk, R McKenna and P Nickerson, Winnipeg, MB, Canada

#318 Factors leading to renal allograft chronic dysfunction.

CMC Oliveira, RMS Mota, RMSP Evangelista, SRF Silva and HH Campos, Fortaleza, Brazil

#319 Renal graft loss after one year: identifying opportunites for intervention using time varied analysis of a large cohort.

JS Gill, GN Nussbaumer, LG DeLuca, W Gourlay, O Djurdejv, A Levin and DN Landsberg, Vancouver, BC, Canada

#320 Is the improvement of renal function in chronic allograft nephropathy, after MMF introduction, relation to cyclosporine reduction?

FBC Lemos, LE Ianhez, BJ Pereira, E Sabbaga and E David-Neto, Sao Paulo, Brazil

#321 Focal mild intimal arteritis without associated parencymal inflammation: rejection or no rejection.

LW Gaber, MF Egidi, V Sing, J Trofe, R Alloway, M Kotb and AO Gaber, Memphis, TN

#322 Risk factors of late renal transplant loss.

Y Sijpkens, I Doxiadis, J de Fijter, M Mallat, L van Es, F Claas and L Paul, Leiden, The Netherlands

#323 Hypercholesterolemia is a risk factor for kidney graft loss from chronic rejection.

K Martin Wissing, D Abramowicz and P Vereerstraeten, Brussels, Belgium

#324 De novo production of anti-HLA donor specific antibodies during acute renal allograft rejection.

M Crespo, M Pascual, N Tolkoff-Rubin, JM Duan, D Fitzpatrick, AB Collins, AB Cosimi, R Colvin and SL Saidman, Boston, MA

#325 Effect of the kidney weight/body weight (Kw/Bw) ratio in the long-term outcome of living kidney transplantation.

K Tanabe, T Tokumoto, N Ishikawa, T Shimizu, H Shinmura, M Harano, M Inui, I Nakajima, S Fuchinoue, T Agishi and H Toma, Tokyo, Japan

Back to Top

Organ Procurement Preservation, Allocation

#326 A comparison of long term outcomes in recipients of renal allografts harvested by laparoscopic versus open technique.

J Nogueira, J Fink, S Blahut, C Cangro, D Klassen, A Wiland, J Flowers, E Cho, S Jacobs, S Bartlett and M Weir, Baltimore, MD

#327 Outcomes of recipients of renal allografts harvested by laparoscopic technique: is there a learning curve?

J Nogueira, A Wiland, J Fink, S Blahut, C Cangro, D Klassen, J Flowers, E Cho, S Jacobs, S Bartlett and M Weir, Baltimore, MD

#328 The influence of donor alcohol consumption on hepatic allograft function.

T Cowling, G Jung, EP Molmenti, RM Goldstein, TA Gonwa, GB Klintmalm and MF Levy, Dallas, TX

#329 Staff experience and donation effectiveness.

P McNamara, C Beasley and H Franz, Boston, MA

#330 The effect of the neutrophile NADPH oxidase inhibitor in infantile heart preservation.

N Haraguchi, S Morita, R Tominaga and H Yasui, Fukuoka, Japan

#331 Cadaver donors greater than age 55: which kidneys to use?

A Humar, L Arrazola, S Kerr, K Gillingham and A Matas, Minneapolis, MN

#332 Lack of correlation between post-transplant coronary artery disease and donor ischemic times.

SR Gundry, J Kirkpatrick, AJ Razzouk, MJ delRio and LL Bailey, Loma Linda, CA

#333 Celsior^® a preservation solution for lung transplantation?

M Strüber, T Wahlers, G Warnecke, J Hohlfeld, T Wittwer, W Harringer and A Haverich, Hannover, Germany

#334 C1-esterase-inhibitor am ameliorates reperfusion injury of the lung.

M Strüber, G Warnecke, P Kim, S Fraund, B Vangerow, H Rückoldt, W Harringer and A Haverich, Hannover, Germany

#335 Adenosine deaminase inhibition increases interstitial adenosine concentrations, post-reperfusion blood flow and survival in rat livers.

MK Schilling, YH Tian and MW Büchler, Bern, Switzerland

AST Poster of Distinction
#336 Effects of an educational segment concerning organ donation and transplantation.

K-H Schulz, D Meier, R Kuhlencordt, C Clausen and X Rogiers, Eppendorf, Germany

#337 Evaluation of high risk organ donors: needless expense or potential source of transplantable organs for HIV+ patients?

C Alexander, E Goldbloom, D Reynolds and W Maley, Baltimore, MD

#338 Potential organ loss in pediatric organ donation.

E Tsai, SD Shemie, D Hebert, L McCarthy, S Furst and PN Cox, Toronto, ON, Canada

#339 Static cold storage versus hypothermic pulsatile preservation in cadaveric kidney transplantation in a single institution (Mexico City).

JA Garcia, Mexico City, Mexico

#340 Does kidney weight (Kw) predict glomerular filtration rate (GFR) in living donors?

JHH Nguyen, EJ Bergstralh, JM Gloor, TK Neuharth, S Sterioff and JA Velosa, Rochester, MN

#341 Celsior^® and perfadex^® for lung preservation. Which solution is best?

H Brandes, J Albes, A Conzelmann, A Kalinka and G Ziemer, Tubingen, Germany

AST Poster of Distinction
#342 The possibility of islet isolation from pancreas harvested from non-heart beating cadaver.

T Deai, Y Tanioka, Y Suzuki, K Suzuki, Y Fujino, Y Iwanaga, M Mitsutsuji, I Matsumoto, Y Ku and Y Kuroda, Kobe, Japan

#343 Investigation of graft function-determining factor in cadaveric renal transplantations.

K Kozaki, M Uchiyama, N Matsuno, E Sakurai, M Kozaki and T Nagao, Tokyo, Japan

#344 Utilization of kidneys from older cadaveric donors older recipients should receive older donor kidneys.

CM Lee, W Prapong, JD Scandling, M Pavlakis, DC Dafoe and EJ Alfrey, Stanford, CA

#345 Donor catecholamine use prevents acute allograft rejection and improves graft survival after cadaveric renal transplantation.

P Schnuelle, D Lorenz, A Mueller, M Trede and FJ van der Woude, Heidelberg, Germany

#346 The liver transplant waiting list: a competing risk (CR) analysis of mortality and transplant probabilities.

GC Stellingwerff, JMA Smits, J De Meester, J de Boer and M Slooff, Leiden, The Netherlands

#347 Superiority of mild hypothermic preservation (20^°C) for pancreatic graft microvasculature using two-layer storage method.

I Matsumoto, Y Suzuki, Y Fujino, Y Tanioka, T Deai, Y Iwanaga, M Mitsutsuji, Y Ku and Y Kuroda, Kobe, Japan

Back to Top

Infectious Complications

#348 Amphotericin B concentrations in autopsy tissues of organ transplant patients administered amphotericin B lipid complex injection.

P Williams, H Waskin, L Bolcsak and C Swenson, Pittsburgh, PA and Princeton, NJ

AST Poster of Distinction
#349 Cyclospoporine pharmacokinetics in HCV infected uremic and renal transplant patients.

L Wolffenbüttel, DD Poli, CB Martins, FJV Veronese, D Saitovitch, RC Manfro and LF Gonçalves, Porto Alegre, Brazil

#350 Interracial differences in posttransplant infections.

SJ Pelletier, R Isaacs, TD Crabtree, TG Gleason, P Lobo, TL Pruett and RG Sawyer, Charlottesville, VA

#351 Oral ganciclovir for CMV prevention after lung transplantation: interim results.

MI Hertz, J Dunitz, RM Bolman, C Gibson, MB King, S Park, SK Savik and K Strasburg, Minneapolis, MN

#352 Systemic fungal infections following orthotopic liver transplantation for acute liver failure.

P Sampathkumar, DJ Plevak and CV Paya, Rochester, MN

#353 Hepatitis C transmission and infection via the donor heart in orthotopic heart transplantation.

PR Pfau, EA Blumberg, D DeNofrio and MR Lucey, Philadelphia, PA

#354 The effect of surgical site infection on outcomes in liver transplantation.

CS Hollenbeak, RS Woodward, MA Schnitzler, JA Lowell, S Shenoy and TK Howard, St. Louis, MO

#355 Hypogammaglobulinemia in heart transplant recipients treated with tacrolimus, mycophenolate, and prednisone.

RK Avery, SD Mawhorter, R Starling, P McCarthy, N Smedira, M Goormastic, D Pelegrin, M Majercik, R Hobbs, K Hoercher, D Cook and JB Young, Cleveland, OH

#356 Human polyoma virus associated interstitial nephritis: a call for modification in immunosuppression and post-transplant monitoring.

H Shidban, N Sattar Khan, S Aswad, A Ahmed and R Mendez, Los Angeles, CA

#357 The epidemiology of cryptococcal infection in solid organ transplantation.

S Kusne, J Madariaga, K McCurry, R Kormos and JJ Fung, Pittsburgh, PA

#358 Efficacy of CMV-IGIV versus standard IGIV in reducing post-transplant CMV infection.

H Shidban, N Park, S Aswad, RG Mendez and R Mendez, Los Angeles, CA

#359 Safety and efficacy of granulocyte-colony stimulating factor in kidney and liver transplant recipients.

N Turgeon, GK Hovingh, JA Fishman, M Doran, N Basgoz, NE Tolkoff-Rubin, AB Cosimi and RH Rubin, Boston, MA

#360 No cardial infection in solid organ transplant recipients.

R Lattes, N Tiraboschi, M Radisic, M Huberman, L Barcan, G Benchetrit, N Jacob, E Cecchini and A Zarate, Buenos Aires, Argentina

#361 HCV infection: no histological progression in kidney transplant recipients.

G Greco, C Alonso, M Rial, J Argento, J Goldberg, O Guardia, M Silva and D Casadei, Buenos Aires, Argentina

#362 The risk of hepatitis B virus (HBV) transmission from HBcAb positive organ donors.

JK Preiksaitis, J Sandhu, J Fenton and M Strautman, Edmonton, AB, Canada

#363 Detection of organ donor EBV load by semiquantitative dilution and/or competitive PCR.

L Butani, LJ Krueger, A Deforest, A Spadaccino, MT ASCP, H Nathan and SP Dunn, Philadelphia, PA

#364 Outcome of pre transplant hepatitis B or C related chronic liver disease in renal transplant recipients.

RK Sharma, KM Sahu, A Gupta, DK Agarwal, S Gulati, A Kumar, M Bhandari and RK Gupta, Lucknow, India

#365 Active CMV infection before lung transplantation: risk factors and clinical implications.

AP Milstone, LM Brumble, JE Lloyd, EW Ely, DA Drennan and JS Dummer, Nashville, TN

#366 Pneumonia in liver transplant recipients in the intensive care unit (ICU): etiology, predictors and outcome.

N Singh, T Gayowski and IR Marino, Pittsburgh, PA

#367 Changes in the level of CMV antigenemia (pp65) in liver transplant recipients receiving oral ganciclovir as CMV prophylaxis.

N Singh, VL Yu, T Gayowski and IR Marino, Pittsburgh, PA

AST Poster of Distinction
#368 Ehrlichiosis after pancreas transplantation

J Trofe, KS Reddy, TK Somerville, MF Egidi, S Flax, RR Alloway, RJ Stratta and AO Gaber, Memphis, TN

#369 Clinical utility of routine urinalysis (UA) screening for infection in transplant (TP) patients (PTS).

JA Bertolatus and D Cox, Iowa City, IA

#370 Outcomes in solid organ transplant patients received granulocyte colony stimulating factor (^G-^CSF) for the management of neutropenia.

A Lo, RR Alloway, J Trofe, HS Amiri, MF Egidi, HP Grewal, RJ Stratta, S Vera and AO Gaber, Memphis, TN

AST Poster of Distinction
#371 Dosing of intravenous ganciclovir for prophylaxis and treatment of cytomegalovirus infection in solid organ transplant recipients.

JA Fishman, MT Doran, AB Cosimi, JG Flood and RH Rubin, Boston, MA

#372 Outcome of interferon-a (IFN-a) treatment in hemodialysis patients and renal transplant recipients with chronic hepatitis C.

T Tokumoto, K Tanabe, T Oshima, N Ishikawa, H Shinmura, T Yagisawa, E Hashimoto, S Fuchinoue, N Hayashi and H Toma, Tokyo, Japan

#373 Pre-emptive therapy against cytomegalovirus disease in renal transplantation - A realistic option?

A Bakran, L Cuevas, H Williams and CYW Tong, Liverpool, UK

#374 Prophylactic and preemptive strategies for control of legionnaire’s disease in heart transplant recipients: a single center 10-years survey in a high-risk environment.

M Hummel, R Kurzuk and R Hetzer, Berlin, Germany

Back to Top

Intrathoracic Organ

#375 Mycophenolate mofetil demonstrates no advantage over azathioprine on steroid withdrawal in cardiac transplant recipients: a single center experience.

RR Baliga, PA Kaiser, MH Drazner, WS Ring, CW Yancy, Jr and MA Solomon, Dallas, TX

#376 Preoperative immunosuppression preempts the effects of mechanical assistance-related sensitization on heart transplant outcome.

AL Heroux, A Tambur, P Meyer, D Koch, F Sun, W Piccione, W Kao, E Winkel, M Saltzberg, V Disesa and MR Costanzo, Chicago, IL

#377 Sexual dysfunction in male cardiac transplant recipients.

E Cohen, S Abbey, H Ross and L Straatman, Toronto, ON, Canada

#378 Detection of HLA antibody is correlated with cardiac allograft rejection.

SK Takemoto, H Gebel, J Chuang, JA Kobashigawa and JM Cecka, Los Angeles, CA and Shreveport, LA

#379 Intermediate-term results of morbidity, mortality and qual-ity of life in older versus younger heart transplant (TX) patients.

JA Haroldson, KD Lake, JK Price, MT Olivari, MR Pritzker and RW Emery, Minneapolis, MN

#380 The beneficial effect of early antiviral treatment for cytomegalovirus (CMV) disease in heart transplant (TX) patients on mortality from graft coronary disease (GCD).

JA Haroldson, KD Lake, FM Hoffman, MR Pritzker, MT Olivari, VR Kshettry and RW Emery, Minneapolis, MN

#381 Intracoronary stents in heart transplant patients who develop transplant coronary artery disease: what is the restenosis rate?

JA Kobashigawa, L Yeatman, J Currier, JD Cassem, JD Moriguchi, MA Hamilton, A Hage, N Kawata and H Laks, Los Angeles, CA

#382 Effective cytomegalovirus prophylaxis with intravenous followed by oral ganciclovir for donor positive/recipient negative mismatch.

J Kobashigawa, B Kubak, R Camara, J Inglish, R Lee, J Moriguchi, M Hamilton, A Hage, N Kawata and H Laks, Los Angeles, CA

#383 Long-term outcome of twice transplanted donor hearts.

J Kobashigawa, M Hummel, B Meiser, M Turina and H Laks, Los Angeles, CA;Berlin and Munich, Germany and Zurich, Switzerland

AST Poster of Distinction
#384 Is viagara (sildenafil) safe and effective in cardiac transplant recipients.

LE Wagoner, RM Giesting, BJ Bell, NC McGuire and WT Abraham, Cincinnati, OH

#385 Sirolimus-based immune suppression in lung transplant recipients.

J Dunitz, RM Bolman, S Park, C Gibson, S Knopik, M Steger and MI Hertz, Minneapolis, MN

#386 Effect of atorvastatin on lipid profiles following heart transplantation

MS Carter, E Loh, DJ Rader, A Kao, PM Smith, SS Fontana and D DeNofrio, New Brunswick, NJ and Philadelphia, PA

#387 Elevated triglyceride levels are associated with early endothelial dysfunction (ED) after heart transplantation (HT).

G Chang, RL Wilensky, E Loh, V See, A Kao, MA Acker and D DeNofrio, Philadelphia, PA

#388 The efficacy of daclizumab, an anti-interleukin receptor antibody, in the prevention of acute rejection in lung transplantation.

CA Amstadt, SM Bhorade, MA McCabe, W Vigneswaran and ER Garrity, Maywood, IL

#389 Our experience with antilymphocyte therapy for the treatment of acute allograft rejections in heart transplant recipients.

GM Mullen, K Malinowska, CE Lawless, BA Pisani, JC Mendez and JA Robinson, Maywood, IL

#390 Outcomes of patients with post-cardiotomy or cardiogenic shock on ventricular assist devices who were referred from community hospitals to be bridged to transplantation.

JC Mendez, GM Mullen, K Malinowska, K Leber, C Bresnahan, CE Lawless, BA Pisani, RC Lichtenberg, JA Robinson, B Foy and M Bakhos, Maywood, IL

#391 Does treated severe acute alllograft rejection effect long-term survival of heart transplant recipients?

GM Mullen, K Malinowska, CE Lawless, BA Pisani, JC Mendez and JA Robinson, Maywood, IL

#392 Effects of preemptive therapy in heart transplant patients with cytomegalovirus antigenemia.

S Burgert, B Radovancevic, M LaRocco, C Thomas, R Radovancevic, LO Gentry and OH Frazier, Houston, TX

#393 Does warfarin increase bleeding in patients undergoing heart transplantation?

JD Verga, JH Levy, NN Buist, MB Allen, AL Smith, W Lu and KR Kanter, Atlanta, GA

#394 Applications of lung volume reduction surgery in lung transplant patients.

C Chaparro, M Hutcheon, C Gutierrez, C Chan, T Todd and S Keshavjee, Toronto, ON, Canada

#395 Malignant neoplasms in cardiac transplant recipients.

RSD Higgins, Detroit, MI

#396 An abnormal donor chest X-ray should not necessarily preclude lung donation.

I Al-Githmi, C Gutierrez, S Herman, C Chaparro, T Todd, M Hutcheon and S Keshavjee, Toronto, ON, Canada

#397 Coronary artery stenting for the treatment of cardiac allograft vasculopathy.

C Tron, M Redonnet, R Koning, F Bouchart, H Eltchaninoff, A Cribier, R Soyer and JP Bessou, Rouen, France

#398 Determinants of homocysteine in heart transplant patients.

E Elstein, B Fagih, S Page and BM Gilfix, Montreal, PQ, Canada

#399 Peripheral vascular disease in cardiac transplantation: abnormal carotid wall thickness.

I Igbal, H Ventura, F Smart, R Hewitt, D Stapleton, D Akers, S Augustine and D Lumpkin, New Orleans, LA

#400 Improvement in right heart failure after tricuspid valve replacement in cardiac transplant patients.

N Giannetti, A AliMollah, T Kato, M Chan, R Cecere, SA Hunt, HA Valantine and RC Robbins, Standford, CA

#401 Hyperhomocysteinemia is common in heart transplant patients but is not correlated with transplant coronary artery disease.

N Giannetti, A Alimollah, SZ Gao, JS Schroeder, SA Hunt and HA Valantine, Stanford, CA

AST Poster of Distinction
#402 Usefulness of pulsed-wave tissue Doppler imaging indices of systolic and diastolic function for rejection investigation and the detection of changes induced by transplant coronary heart disease.

M Dandel, M Hummel, J Müller, R Meyer, R Ewert and R Hetzer, Berlin, Germany

#403 Eight year follow-up of patients bridged to cardiac transplantation with Jarvik-7 total artificial heart.

GM Mullen, K Malinowska, CE Lawless, BA Pisani, JC Mendez, JA Robinson, R Pifarre, B Foy and M Bakhos, Maywood, IL

#404 Our experience with the heart mate pneumatic and vented electric left ventricular assist devices.

GM Mullen, K Malinowska, KL Martin, LF Michel, M Laff, CE Lawless, BA Pisani, JC Mendez, JA Robinson, R Pifarre, B Foy and M Bakhos, Maywood, IL

#405 Relationship between cyclosporine, creatinine, and homocysteine in cardiac transplant patients.

BM Gilfix, M Cantarovich and E Elstein, Montreal, PQ, Canada

AST Poster of Distinction

#406 Renal hemodynamic effects of L-arginine and sodium-nitroprusside in heart transplant recipients.

J Koller-Strametz, M Wolzt, C Köppel, D Putz, W Wisser, C Mensik, HG Eichler, G Laufer and L Schmetterer, Vienna, Austria

AST Poster of Distinction

#407 Predictors of long-term renal function after heart transplantation.

M Cantarovich, J Barkun, A Hirsh, P Carroll, E Elstein, P Ergina and B de Varennes, Montreal, PQ, Canada

#408 Pretransplant plasmapheresis and immunoglobulin G in patients with an elevated panel reactive antibody.

BA Pisani, K Malinowska, GM Mullen, CE Lawless, JC Mendez and JA Robinson, Maywood, IL

#409 Tacrolimus or cyclosporine for immunosuppression after HTx: which treatment reveals more systemic side effects during long term follow up?

BM Meiser, D Schmidt, M Pfeiffer, W v. Scheidt, V Klauss, S Wildhirt, P Überfuhr, H Reichenspurner and B Reichart, Munich, Germany

#410 Renal function in cardiac transplant recipients is not improved by pre-transplant LVAD bridging.

A Beniaminovitz, AD Simon and DJ Cohen, New York, NY

#411 Incidence of transplant coronary artery disease: influence of surgical ischemic time.

JF Legare, H Haddad, S Haddad, KJ Buth and G Hirsch, Halifax, NS, Canada

#412 Cutaneous microcirculation during help-LDL-apheresis in cardiac allograft recipients with severe hypercholesterolemia.

J-W Park, C Mrowietz, G Lässig, S Schüler and F Jung, Dresden and Homburg, Germany

#413 MMF-dose adjustments based on MPA-trough levels after heart transplantation: difference between high and low dose pharmacokinetics.

BM Meiser, D Schmidt, M Pfeiffer, J Schirmer, H Reichenspurner, D Paulus, D Seidel and B Reichart, Munich, Germany

#414 Preliminary data regarding the use of interleukin-2-receptor antibody (daclizumab) in lung transplantation.

J Jover, H Latifi and A Frost, Houston, TX

#415 10 Years experience with lung and heart-lung transplantation in primary and secondary pulmonary hypertension.

U Franke, K Wiebe, W harringer, T Franke, M Strüber, J Niedermeyer, HG Fieguth, T Wahlers and A Haverich, Hannover, Germany

#416 Laser Doppler flowmetry detects early risk of tracheal anastomotic complications after lung transplantation.

TA Hyytinen and M Halme, Helsinki, Finland

#417 Complete conversion of immunosuppression from cyclosporine to mycophenolate mofetil in patients with renal insufficiency after HTX.

BM Meiser, J Schirmer, D Schmidt, H Gulbins, H Treede, M Pfeiffer, W v. Scheidt, H Reichenspurner and B Reichart, Munich, Germany

#418 Lung transplant in sarcoidosis.

I Nizami, Houston, TX

#419 Is cocaine use in the donor a risk factor for increased morbidity and mortality following cardiac transplantation?

K Hoercher, JB Young, NS Smedira, M Banbury, J Navia and PM McCarthy, Cleveland, OH

#420 Prevalence of bronchiolitis obliterans syndrome (BOS) in lung transplant recipients treated with mycophenolate mofetil (MMF).

T Bîrsan, A Zuckermann, E Deviatko, S Taghavi, G Dekan and W Klepetko, Vienna, Austria

#421 Improved prevention of graft arteriosclerosis with thymoglobulin induction therapy in long term patients after cardiac transplantation.

A Zuckermann, M Grimm, P Ofner, R Ullrich, E Wolner and G Laufer, Vienna, Austria

#422 Cardiac transplantation in patients with pre-existing malignancies.

I Penn, Cincinnati, OH

#423 Angiographic follow up of percutaneous revascularization for transplant coronary artery disease.

S Dempsey, C D’Amico, W Weintraub, J Lutz, Z Ghazzal, A Smith and W Book, Atlanta, GA

#424 Early acute rejection in heart allografts: QT-alterations in the 12-lead surface ECG.

G Tenderich, J Jahanyar, L Hornik, S Reif, W Deyerling, H Mannebach, R Koerfer and MM Koerner, Bad Oeynhausen, Germany

Back to Top

Return to the Agenda